Business Wire
BusinessMcDonald’s shares fall nearly 19% in six months as U.S. traffic worries investorsThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessMcDonald’s shares fall nearly 19% in six months as U.S. traffic worries investorsThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessMcDonald’s shares fall nearly 19% in six months as U.S. traffic worries investorsThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessMcDonald’s shares fall nearly 19% in six months as U.S. traffic worries investorsThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex Times
Back to front
CFRA flags downside for Walmart shares if it holds its outlook steady after upcoming earnings
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 12:04 PM EDT

CFRA flags downside for Walmart shares if it holds its outlook steady after upcoming earnings

Ahead of Walmart’s second-quarter earnings report, CFRA Research said the stock could react negatively if the retailer does not lift its forward guidance.

2 min readEditor-approved Apex article

Walmart is set to report second-quarter results on Thursday before the opening bell, and CFRA Research is indicating that investors will focus less on the headline earnings number and more on what the company says about the road ahead.

In a preview shared with Yahoo Finance, CFRA senior vice president of equity research Arun Sundaram framed the key risk for the stock around whether Walmart raises its outlook. The note was tied to the idea that, without an upward revision to guidance, shares may face selling pressure as the market looks for confirmation that the company’s demand and margin trajectory can sustain momentum.

Walmart’s earnings timing matters for traders because pre-market releases often set the direction for the day’s trading and can quickly reshape expectations across analysts’ models. With the quarter’s report scheduled for before the open, the market will be positioned early to price in management’s comments on retail performance, costs, and consumer spending.

CFRA’s stance reflects a broader market pattern for large retailers: after a period when investors have demanded evidence of resilient foot traffic and steady profitability, guidance becomes a proxy for confidence. If management does not raise its outlook, it can be interpreted as caution about demand conditions, competitive intensity, or the durability of cost improvements.

The preview also underscores how the stock can trade on incremental changes rather than just the reported quarter. Even if Walmart posts results that meet or beat expectations, a failure to improve guidance can lead to a negative interpretation, particularly if investors had expected management to announcement a stronger path for upcoming quarters.

Walmart operates in a sector where both revenue growth and margin discipline are watched closely, since the business blends a high-volume retail engine with mix effects from categories and shopping behavior. The market typically wants clarity on whether performance is coming from pricing, from operational efficiencies, or from improved customer demand, and guidance is where management tends to translate those indicates into forward-looking expectations.

For shareholders and analysts, the immediate next step is to see what Walmart discloses alongside its earnings. The market will look for whether the company chooses to adjust its outlook, and how it describes underlying trends that could justify any change.

What is not clear from the preview alone is the specific level of guidance Walmart would need to raise, or the exact earnings and guidance figures CFRA expects. The interview also does not provide detailed quarterly metrics, so the timing and direction of the stock reaction will depend on what Walmart actually reports and how management characterizes its forward trajectory.

Why It Matters

  • For large retailers, forward guidance can drive the share price more than the reported quarter, especially when expectations already price in stability.
  • Investors may use Walmart’s guidance decision as a read-through on consumer demand and profitability durability.
  • Because the earnings are set for before the open, guidance comments may quickly reset trading expectations for the rest of the day.
  • If Walmart keeps outlook unchanged, the market could interpret it as caution on near-term conditions even if results are solid.

Sources

Key Facts

  • Walmart (WMT) is scheduled to report second-quarter earnings on Thursday before the opening bell.
  • CFRA Research, via Arun Sundaram, said the stock could fall if Walmart does not raise its outlook.
  • The CFRA commentary emphasizes the importance of forward guidance, not just the quarterly earnings print.
  • The preview was shared through a Yahoo Finance video ahead of the earnings release.

Retail & Consumer Related

Aug 19, 12:45 PM EDT
The Apex Times

Target tops Q2 estimates as sales rise 5.3%, and lifts its fiscal 2026 outlook

The retailer reported a quarter that beat earnings expectations, citing stronger in-store traffic, growth in digital sales, and improved performance across key categories. Management also pointed to tariff-related refunds supporting profitability and raised its fiscal 2026 guidance.

Target tops Q2 estimates as sales rise 5.3%, and lifts its fiscal 2026 outlook
The Apex Times